Is retroelement-based gene editing a safer alternative to CRISPR-Cas approaches?

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.

$10.2M NIH grant awarded to study risk factors for malignant arrhythmias in mitral valve prolapse

Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute

September 27, 2023

Differential gene expression linked to alcohol use disorder, offering new treatment possibilities

Researchers identified key gene expression differences in addiction-relevant brain regions that provide new insights into alcohol use disorder and potential therapeutic targets.

October 14, 2024

BeiGene opens biologics manufacturing facility in New Jersey, US

BeiGene’s flagship biologics manufacturing facility and clinical R&D centre at the Princeton West Innovation Campus, Hopewell, New Jersey. Credit: BeiGene /Business Wire. BeiGene has announced

July 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.